Addendum: sartan treatment during pregnancy.

[1]  C. Garel,et al.  Developmental toxicity of the angiotensin II type 1 receptor antagonists during human pregnancy: a report of 10 cases , 2005, BJOG : an international journal of obstetrics and gynaecology.

[2]  J. Friedman,et al.  Angiotensin II receptor antagonist treatment during pregnancy. , 2005, Birth defects research. Part A, Clinical and molecular teratology.

[3]  F. Muller,et al.  Fetal Toxic Effects of Angiotensin II Receptor Antagonists: Case Report and Follow-Up after Birth , 2005, The Annals of pharmacotherapy.

[4]  N. Berkane,et al.  Fetal toxicity of valsartan and possible reversible adverse side effects. , 2004, Birth defects research. Part A, Clinical and molecular teratology.

[5]  R. Cox,et al.  Defective embryogenesis with angiotensin II receptor antagonists in pregnancy , 2003, BJOG : an international journal of obstetrics and gynaecology.

[6]  R. Aggarwal,et al.  Losartan induced fetal toxicity , 2003, Indian journal of pediatrics.

[7]  C. Schaefer.  Angiotensin II-receptor-antagonists: further evidence of fetotoxicity but not teratogenicity. , 2003, Birth defects research. Part A, Clinical and molecular teratology.

[8]  J. Motte,et al.  Perinatal/Neonatal Case Presentation: Neonatal Acute Renal Failure Secondary to Maternal Exposure to Telmisartan, Angiotensin II Receptor Antagonist , 2003, Journal of Perinatology.

[9]  L. Wilton,et al.  The safety of valsartan: results of a postmarketing surveillance study on 12 881 patients in England , 2002, Journal of Human Hypertension.

[10]  A. Benachi,et al.  Fetal toxic effects and angiotensin-II-receptor antagonists , 2001, The Lancet.

[11]  M. Nageotte,et al.  Fatal Fetal Outcome with the Combined Use of Valsartan and Atenolol , 2001, The Annals of pharmacotherapy.

[12]  A. Wingen,et al.  Angiotensin-II-receptor inhibitors in pregnancy , 2001, The Lancet.

[13]  A. Hagiwara,et al.  Losartan and fetal toxic effects , 2001, The Lancet.